Corvus Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Corvus Pharmaceuticals reports reduced net loss in Q3 2025 driven by warrant revaluation, positive clinical data for soquelitinib, but faces substantial doubt about its ability to continue as a going concern.
NASDAQ
Corvus Pharmaceuticals reported a net income for the first six months of 2025 driven by a warrant revaluation gain, while advancing its lead drug candidates soquelitinib and ciforadenant in clinical trials.
NASDAQ
Corvus Pharmaceuticals reports a net income of $15.2 million for Q1 2025, primarily due to a significant decrease in warrant liability, while continuing to advance its clinical development programs.
NASDAQ
10-Q: Corvus Pharmaceuticals Reports Q3 2024 Results, Highlights Clinical Progress and Financial Position
Corvus Pharmaceuticals reported a net loss of $40.2 million for Q3 2024, while highlighting clinical advancements and a strengthened financial position through recent capital raises.
NASDAQ
Corvus Pharmaceuticals reports a net loss of $10.0 million for the first six months of 2024, while advancing its clinical programs for soquelitinib, ciforadenant, and mupadolimab.
NASDAQ
Corvus Pharmaceuticals reports a net loss of $5.7 million for the first quarter of 2024, while advancing its clinical programs and securing additional funding.